Back to Search
Start Over
Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C
Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C
- Source :
- Clinical drug investigation. 34(12)
- Publication Year :
- 2014
-
Abstract
- Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner.Chronic hepatitis C patients treated with ribavirin combined with peg-IFN-α2a (N = 109) or -α2b (N = 114) were studied. Hepatitis C virus RNA quantitation was performed by Cobas TaqMan 5 min before treatment start and subsequently after 48/72 h and 7, 14, 28 and 90 days. Antiviral effect was assessed in terms of viraemia changes over treatment. Histology grading and staging, interleukin-28B (IL28B) status and baseline viral genotype, alanine aminotransferase, gamma glutamyltransferase and glucose were analysed.Viraemia decline after 48/72 h and 7 days was significantly greater with peg-IFN-α2b (1.96 and 2.12 vs 1.49 and 1.20 log10 IU/mL with peg-IFN-α2a; p0.001). Differences were of larger extent in patients with advanced fibrosis (p = 0.002), genotype 1 infection (p = 0.002) and CT/TT genotypes of IL28B (p = 0.001). A rebound in viral load was observed significantly more often after the first dose in patients treated with peg-IFN-α2b (78 vs 28 % in those with peg-IFN-α2a; p = 0.0001). Differences between peg-IFNs disappeared by day 28 of treatment.There are significant pharmacodynamic differences between peg-IFN-α2a and -α2b in the early phase of chronic hepatitis C treatment. The greater early viral decline observed with peg-IFN-α2b was essentially confined to 'difficult to treat' patients. Whether this could affect response-guided treatment decision making, as well as triple drug regimens, needs to be assessed.
- Subjects :
- Adult
Male
Pharmacology toxicology
Treatment outcome
Alpha interferon
macromolecular substances
Pharmacology
Interferon alpha-2
Antiviral Agents
Polyethylene Glycols
Cohort Studies
Young Adult
Pharmacotherapy
Pharmacokinetics
Chronic hepatitis
Pegylated interferon
Medicine
Humans
Pharmacology (medical)
Aged
Retrospective Studies
business.industry
technology, industry, and agriculture
Interferon-alpha
General Medicine
Hepatitis C
Hepatitis C, Chronic
Middle Aged
medicine.disease
Virology
Recombinant Proteins
Treatment Outcome
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 11791918
- Volume :
- 34
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Clinical drug investigation
- Accession number :
- edsair.doi.dedup.....afc41b50e4ee7973665c745f714c8de0